Drug Topics

JULY 29, 2024

Check out this list of our top 10 most read stories from July 2024.

485

485

PharmaVoice

JULY 29, 2024

A brain-on-a-chip developer says better preclinical modeling could help move the needle.

162

162

Drug Topics

JULY 29, 2024

Researchers analyzed the prominence of opioid and methadone prescriptions for hospitalized newborns with substantial morbidities.

Hospitals 309

Hospitals 309

Pharmacy Times

JULY 29, 2024

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

FDA 146

FDA 146

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JULY 29, 2024

A roundtable session discussed the real-world implications of applying Direct and Indirect Remuneration (DIR) fees at the point of sale rather than through retroactive clawback.

Community Pharmacies 309

Community Pharmacies 309

STAT

JULY 29, 2024

Bird flu snapshot: This is the latest installment in a series of regular updates on the H5N1 flu outbreak in dairy cows that STAT is publishing on Monday mornings. To read future updates, you can also subscribe to STAT’s Morning Rounds newsletter. A network of nascent vaccine manufacturers in low- and middle-income countries will soon start preliminary work to develop messenger RNA vaccines targeting the H5N1 bird flu virus, an effort that could speed production during a pandemic, should

Vaccines 145

Vaccines 145

STAT

JULY 29, 2024

Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular dystrophy, STAT has learned. The incident raises questions about the financial ties between Sarepta and the advocacy group, Parent Project Muscular Dystrophy, and whether the drugmaker uses its money to influence, or even muzzle, debate over its Duchenne medicines.

145

145

Drug Topics

JULY 29, 2024

Erin Albert, Vice President of Pharmacy Relations and Chief Privacy Officer at Mark Cuban Cost Plus Drug Company, PBC, discussed the changing landscape regarding prescription drug pricing.

282

282

STAT

JULY 29, 2024

With the number of U.S. dairy herds infected with H5N1 bird flu rising almost daily, fears are growing that the dangerous virus cannot be driven out of this species. That belief is amplifying calls for the development of flu shots for cows. Multiple animal vaccine manufacturers are reportedly at work trying to develop such products. And the U.S. Department of Agriculture is eagerly encouraging the effort, detailing in a notice last week what kinds of evidence would be needed to win licensing app

Vaccines 145

Vaccines 145

Drug Topics

JULY 29, 2024

Emily Endres, BSPS, vice president of pharmacy at Innovaccer discuss the evolution of healthcare and provides insights into the industry’s next phase.

282

282

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JULY 29, 2024

New blood tests could help doctors diagnose  Alzheimer’s  disease faster and more accurately, researchers reported Sunday – but some appear to work far better than others. It’s tricky to tell if memory problems are caused by Alzheimer’s. That requires confirming one of the  disease’s hallmark signs  — buildup of a sticky protein called beta-amyloid — with a hard-to-get brain scan or uncomfortable spinal tap.

144

144

Drug Topics

JULY 29, 2024

Jon Minkin, Enterprise Account Executive at NimbleRx and pharmacy technology expert, discussed how his company can help independent pharmacies unlock revenue opportunities.

Independent Pharmacies 247

Independent Pharmacies 247

Pharmacy Times

JULY 29, 2024

Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.

FDA 144

FDA 144

STAT

JULY 29, 2024

WASHINGTON — LGBTQ+ dating app Grindr is tapping into the Washington lobbying world amid legislative battles over reproductive health care access. The “ Global Gayborhood” has hired The Daschle Group, founded by former Senate Democratic leader Tom Daschle, to lobby on “HIV prevention; LGTBQ family formation challenges including surrogacy and IVF,” according to federal disclosures filed last week.

140

140

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

JULY 29, 2024

An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.

139

139

STAT

JULY 29, 2024

Around November, Kivo Health, a telehealth provider of pulmonary rehabilitation services, will need to start warning older patients that their sessions may not be covered by Medicare in the new year. Kivo was founded in 2022, and it’s covered by Medicare thanks to telehealth flexibilities passed by Congress during the Covid-19 pandemic. Those flexibilities expanded what kinds of care people on Medicare can receive over telehealth — but they are set to expire at the end of 2024.

133

133

PharmaVoice

JULY 29, 2024

The mid-stage failure leaves the success of the expensive partnership hanging on a drug that’s already suffered its own setback.

130

130

STAT

JULY 29, 2024

The human body works hard to prevent outside substances from entering the brain — which makes it a challenge to get drugs into the brain to treat neurological diseases. A study published today in Nature Microbiology opens the door to a potential clever solution, showing how Toxoplasma gondii, a parasite that is able to cross the blood-brain barrier, can be engineered to treat a brain development disorder in mice.

Communication 132

Communication 132

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

JULY 29, 2024

The similarities were shown for both the US formulation and the EU formulation.

127

127

STAT

JULY 29, 2024

Americans are facing at least two prescription drug crises simultaneously. One is the outrageously high cost of drugs, which runs to more than $500 billion per year. The other relates to extreme drug shortages requiring rationing of lifesaving medications. Crises can generate opportunities. Mark Cuban, the wildly successful entrepreneur and NBA owner, has committed himself to solving these two problems.

129

129

Fierce Healthcare

JULY 29, 2024

HealthEquity, a prominent health savings account administrator, has disclosed a data breach it says impacted 4.3 million people. | The company filed a notice with Maine's attorney general and revealed that it received an alert on March 25 about a potential security incident, and then proceeded to conduct an investigation.

125

125

pharmaphorum

JULY 29, 2024

Ipsen gets CHMP backing for Alagille syndrome therapy odevixibat, with a new brand name that it hopes will unlock orphan status in the EU

116

116

Fierce Healthcare

JULY 29, 2024

The Centers for Medicare & Medicaid Services is creating a voluntary demonstration program to support changes to Medicare Part D under the Inflation Reduction Act.

120

120

pharmaphorum

JULY 29, 2024

Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.The alliance with Health Innovation Oxford & Thames Valley (Oxford HIN) is focusing on Care for MDD, an app-based DTx that has been co-developed by Otsuka and digital health specialist Click Therapeutics.

FDA 116

FDA 116

Outsourcing Pharma

JULY 29, 2024

The Rainwater Charitable Foundation (RCF), in collaboration with CurePSP and the Aging Mind Foundation (AMF), has announced the allocation of $2 million in grants to support groundbreaking research in primary tauopathies.

114

114

pharmaphorum

JULY 29, 2024

Flagship Pioneering signs another strategic-level deal with a big pharma group, with GSK agreeing an alliance potentially worth more than $7 billion

115

115

STAT

JULY 29, 2024

You’re reading the web version of Health Care Inc.,  STAT’s weekly newsletter  following the flow of money in medicine.  Sign up  to get it in your inbox every Monday. Inside UnitedHealth’s physician empire UnitedHealth Group is everywhere. Increasingly, it is starting to feel like the Standard Oil of health care.

Hospitals 108

Hospitals Insurance 108

pharmaphorum

JULY 29, 2024

NICE and pharma groups AstraZeneca and Daiichi Sankyo have been unable to agree on a price for Enhertu in HER2-low breast cancer.

111

111

Fierce Healthcare

JULY 29, 2024

The enhanced subsidies available for Affordable Care Act plans have been the key to driving massive enrollment growth, and rolling them back would likely lead to a massive spike in premium payments | The enhanced subsidies available for Affordable Care Act plans have been the key to driving massive enrollment growth, and rolling them back would likely lead to a massive spike in premium payments, according to a new report.

106

106

pharmaphorum

JULY 29, 2024

This comprehensive guide provides pharmaceutical companies with valuable insights into biologics contract manufacturing, including the role of CDMOs and key considerations for successful partnerships.

Pharmaceutical Companies 111

Pharmaceutical Companies Pharmaceutical Companies 111

STAT

JULY 29, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that oh-so familiar routine of online meetings, phone calls, and deadlines has returned. But you knew this would happen, yes? After all, the world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup or three of stimulation.

Pharmaceutical Companies 106

Pharmaceutical Companies Pharmaceutical Companies 106

Fierce Pharma

JULY 29, 2024

Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. | Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition.

FDA 105

FDA 105

pharmaphorum

JULY 29, 2024

Shares in NewAmsterdam Pharma were sliding today after it reported a phase 3 trial of obicetrapib that met its primary objective but didn't meet the expectations of some analysts and investors.The BROOKLYN study compared the oral CETP inhibitor to a placebo given on top of maximum tolerated doses of other lipid-modifying therapies, like statins and ezetimibe, in patients with heterozygous familial hypercholesterolaemia (HeFH), a genetic condition that raises blood cholesterol and the risk of hea

105

105